华润医药2024年年报

CONTENTS 02Corporate Profile03Corporate Information06Definitions12Chairman’s Statement16Highlights of the Year and Awards24Financial Highlights25Management Discussion and Analysis65Corporate Governance Report91Biographies–Directors and Senior Management103Report of the Directors127Independent Auditor’s Report134Consolidated Statement of Profit or Loss135Consolidated Statement of Profit or Loss andOtherComprehensive Income136Consolidated Statement of Financial Position138Consolidated Statement of Changes in Equity140Consolidated Statement of Cash Flows143Notes to the Consolidated Financial Statements 公司簡介Corporate Profile 華潤醫藥集團有限公司（股份代號：3320）是中國領先的綜合醫藥公司，業務範疇覆蓋醫藥及保 健 產 品 的 生 產、分 銷 及 零 售。本 集 團 成 立 於二零零七年，現已發展成中國前兩大醫藥製造商兼中國前三大醫藥產品分銷商（按收益）。 China Resources Pharmaceutical Group Limited (stock code: 3320) is a leadingintegrated pharmaceutical company in China. Our business encompassesmanufacturing, distribution and retail of pharmaceutical and healthcareproducts. Since the establishment in 2007, the Group has developed intoone of the top 2 pharmaceutical manufacturers and one of the top 3pharmaceutical distributors (by revenue) in China. 本公司於二零一六年十月在香港成功完成全球發 售。我 們 的 製 造 業 務 涵 蓋 研 發、生 產 及 銷 售醫 藥 及 保 健 產 品。我 們 生 產840種 產 品，其 中439種產品進入了國家醫保目錄。產品組合包括化學藥品、中藥、生物藥以及營養保健品，覆蓋廣 泛 治 療 領 域，包 括 心 血 管、消 化 道 和 新 陳 代謝、大容量靜脈注射液、兒科、呼吸系統、皮膚等。此 外，我 們 擁 有「999」、「東 阿 阿 膠」、「雙鶴」、「紫竹」、「江中」、「博雅」、「昆中藥」等多個 馳 名 品 牌，業 務 覆 蓋 感 冒、胃 腸、皮 膚、兒科、骨科、血製品等品類，未來將積極向健康管理、慢病管理產品延伸，滿足中國家庭從預防、保健、治療、康復，全周期、多層次的健康需求。 In October 2016, the Company successfully completed its global offeringin Hong Kong. Our manufacturing business encompasses the research anddevelopment, manufacturing and sale of pharmaceutical and healthcareproducts. We manufacture 840 products, 439 of which were included in theChina’s national reimbursement drug list. The products comprise chemicaldrugs, Chinese medicines and biological drugs as well as nutritional andhealthcare products, covering a wide range of therapeutic areas includingcardiovascular, alimentary tract and metabolism, large-volume intravenousinfusion, pediatrics, respiratory system, dermatology, etc. Moreover, we owna range of famous brands, such as“999”,“Dong-E-E-Jiao”,“Double Crane”,“Zizhu”,“Jiangzhong”,“Boya”and“Kun Zhong Yao”, covering therapeuticareas including cold, gastroenterology, dermatology, pediatrics, orthopedics,plasma products, among others. In future, we will actively expand into healthmanagement and products for chronic disease management to meet the full-cycle and multi-dimensional healthcare needs of Chinese households fromprevention, healthcare, therapy to recovery. 我們視研發創新為長期發展的重要驅動力，持續 加 大 研 發 投 入，擁 有 一 個 全 國 重 點 實 驗 室、三個國家工程技術研究中心、四個國家級企業技術中心，以及90餘個省市級研發平台，並設有博士後科研工作站。 We regard R&D and product innovation as important drivers for our long-term growth and consistently increase the investment in R&D activities. Weoperate one state key laboratory, three national engineering research centers,four national enterprise technology centers, as well as over 90 provincialmunicipal-level R&D platforms, and a postdoctoral research workstation. 憑藉我們全面的產品供應及廣泛的分銷網絡，我們向中國的醫院及其他醫療機構直接分銷產品。我們經營著一個由超過220個物流中心構成的全國性分銷網絡，戰略性覆蓋中國28個省、直轄市及自治區，客戶數量超27萬家，其中包括二、三級醫院1.1萬餘家，基層醫療機構客戶約12萬家。另外，我們經營中國最大零售藥房網絡之一，我們以「德信行」等全國或地區性的優質品牌來經營708家零售藥房，其中包括DTP專業藥房270家（含「雙通道」藥店182家）。 Leveraging our comprehensive product supply and wide distribution networks,we directly distribute products to hospitals and other medical institutionsacross the country. We operate a national distribution network comprisingover 220 logistics centers strategically across 28 provinces, municipalities andautonomous regions in China, with more than 270,000 clients, including over11,000 second- and third-class hospitals and approximately 120,000 primarymedical institution clients. In addition, we operate one of the largest retailpharmacy networks in China, comprising 708 retail pharmacies under nationalor regional premium brands such as“Teck Soon Hong (德 信 行)”, including270 DTP specialty pharmacies (which cover 182“dual channel (雙 通 道)”pharmacies). 公司資料Corporate Information BOARD OF DIRECTORS Chairman and Executive DirectorMr. Bai Xiaosong 白曉松先生 Executive Director and Vice PresidentMr. Tao Ran 陶然先生 Executive Director and Chief Financial OfficerMdm. Deng Rong 鄧蓉女士 Non-executive DirectorsMdm. Guo WeiMr. Sun YongqiangMr. Guo ChuanMdm. Jiao Ruifang 郭巍女士孫永強先生郭川先生焦瑞芳女士 Independent non-executive DirectorsMdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian 盛慕嫻女士郭鍵勳先生傅廷美先生張克堅先生 AUDIT COMMITTEE 盛慕嫻女士（主席）郭巍女士焦瑞芳女士郭鍵勳先生傅廷美先生張克堅先生 Mdm. Shing Mo Han Yvonne(Chairman)Mdm. Guo WeiMdm. Jiao RuifangMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian NOMINATION COMMITTEE 白曉松先生（主席）盛慕嫻女士郭鍵勳先生傅廷美先生張克堅先生 Mr. Bai Xiaosong(Chairman)Mdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian REMUNERATION AND APPRAISAL COMMITTEE 郭鍵勳先生（主席）孫永強先生盛慕嫻女士傅廷美先生張克堅先生 Mr. Kwok Kin Fun(Chairman)Mr. Sun YongqiangMdm. Shing Mo Han YvonneMr. Fu TingmeiMr.